Cargando…
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
IMPORTANCE: High costs and risks of research and development (R&D) have been used to justify the high prices of cancer drugs. However, what the return on R&D investment is, and by extension what a justifiable price might be, is unclear. OBJECTIVE: To compare incomes from the sales of cancer...
Autores principales: | Tay-Teo, Kiu, Ilbawi, André, Hill, Suzanne R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324319/ https://www.ncbi.nlm.nih.gov/pubmed/30644967 http://dx.doi.org/10.1001/jamanetworkopen.2018.6875 |
Ejemplares similares
-
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
por: Dahlén, Amelia D., et al.
Publicado: (2022) -
Strategies of drug companies to optimize the sales of their psychiatric drugs
por: Whitaker, Robert
Publicado: (2007) -
Sold!: the art of relationship sales
por: Darley, Paul, et al.
Publicado: (2018) -
Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023) -
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)